US 12,186,306 B2
Methods of treatment for cystic fibrosis
Bartlomiej Borek, San Diego, CA (US); Weichao George Chen, San Diego, CA (US); Rudy Gunawan, Apex, NC (US); Eric Haseltine, Melrose, MA (US); Nitin Nair, Hopkinton, MA (US); Porntula Panorchan, Orlando, FL (US); and Patrick Sosnay, West Roxbury, MA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Dec. 9, 2021, as Appl. No. 17/546,649.
Claims priority of provisional application 63/150,434, filed on Feb. 17, 2021.
Claims priority of provisional application 63/124,575, filed on Dec. 11, 2020.
Claims priority of provisional application 63/123,928, filed on Dec. 10, 2020.
Prior Publication US 2022/0184049 A1, Jun. 16, 2022
Int. Cl. A61K 31/4375 (2006.01); A61K 9/20 (2006.01); A61K 31/4045 (2006.01); A61K 31/47 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 9/2054 (2013.01); A61K 31/4045 (2013.01); A61K 31/47 (2013.01)] 22 Claims
 
1. A method of treating cystic fibrosis comprising daily administration of:
(a) 250 mg of Compound I:

OG Complex Work Unit Chemistry
or an equivalent amount of a pharmaceutically acceptable salt thereof; and
(b) 21.24 mg Compound II calcium salt hydrate Form D:

OG Complex Work Unit Chemistry
 and
(c) 100 mg of Compound III:

OG Complex Work Unit Chemistry
or an equivalent amount of a pharmaceutically acceptable salt thereof.